Zymeworks Inc. (ZYME) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Zymeworks Inc. (ZYME:NASDAQ), powered by AI.

Current Price
$26.71
P/E Ratio
-16.5
Market Cap
2.0B
Sector
Healthcare
What is the Zymeworks Inc. stock price forecast?

Zymeworks Inc. is currently trading at $26.71. View real-time AI analysis on Alpha Lenz.

What is Zymeworks Inc. insider trading activity?

View the latest insider trading data for Zymeworks Inc. on Alpha Lenz.

What is Zymeworks Inc.'s P/E ratio?

Zymeworks Inc.'s P/E ratio is -16.5.

Zymeworks Inc.

NASDAQ · ZYME
$26.71
Ask about Zymeworks Inc.'s future dividend policy...
Alpha Chat Insight

Zymeworks Inc. trades at a P/E of -16.5 (undervalued) with modest ROE of -30.5%. 3Y revenue CAGR of 60.8% highlights clear growth momentum.

Ask for details

Company Overview

Zymeworks Inc. is a biotechnology company that focuses on innovating biotherapeutics for the treatment of cancer and autoimmune diseases. The company's core mission revolves around developing novel, multifunctional therapeutics with the potential to improve efficacy and reduce side effects compared to conventional cancer treatments. Zymeworks utilizes its proprietary platforms, such as the Azymetric and EFECT technologies, which enable the creation of multifunctional antibody therapeutics. These assets are significant in sectors such as oncology and immunology, addressing unmet needs with therapies aimed at complex and difficult-to-treat conditions. Based in Canada, Zymeworks collaborates with leading global pharmaceutical companies to enhance the reach and impact of its research. In the financial market, Zymeworks Inc. is notable for its strategic partnerships and potential for contributing to advancements in precision medicine, emphasizing its role not only in scientific innovation but also as a key player in the biotech industry's approach to personalized healthcare solutions.

CEOMr. Kenneth H. Galbraith C.A.
SectorHealthcare
IndustryBiotechnology
Employees273

Company Statistics

FY 2024

Profile

$2.03BMarket Cap
$76.30MRevenue
0.00Shares Out
273Employees

Margins

N/AGross
-120.72%EBITDA
-157.03%Operating
-152.82%Pre-Tax
-160.80%Net

Valuation

-16.51P/E
5.98P/B
26.55EV/Sales
-21.48EV/EBITDA
-17.91P/FCF

Growth (CAGR)

60.79%Rev 3Yr
20.90%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-23.51%ROA
-30.54%ROE
-22.95%ROIC

Financial Health

$66.10MCash & Cash Equivalents
$58.22MNet Debt
36.70%Debt/Equity
N/AInterest Cov
Alpha Chat Insight

Zymeworks Inc. trades at a P/E of -16.5 (undervalued) with modest ROE of -30.5%. 3Y revenue CAGR of 60.8% highlights clear growth momentum.

Ask for details

Frequently Asked Questions

Zymeworks Inc. (ticker: ZYME) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 273 employees. Market cap is $2.0B.

The current price is $26.71 with a P/E ratio of -16.51x and P/B of 5.98x.

ROE is -30.54% and operating margin is -157.03%. Annual revenue is $76M.

Alpha Lenz
Singapore
CEO: Kyungtae Kim | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2025 Treasurer. All rights reserved.
Zymeworks Inc. (Healthcare) Stock Forecast & Analysis $26.71 | Alpha Lenz